For research use only. Not for therapeutic Use.
Prostaglandin D<sub>2</sub> (PGD<sub>2</sub>; Item No. <span class=/itemid/>12010</span>) is synthesized by hematopoietic-<wbr></wbr>type PGD-<wbr></wbr>synthase (H-<wbr></wbr>PGDS) in mast cells and is released in large quantities during allergic and asthmatic anaphylaxis. PGD<sub>2</sub> is also produced in the brain by lipocalin-PGD-<wbr></wbr>synthase also known as β-<wbr></wbr>trace. In the brain, PGD<sub>2</sub> produces normal physiological sleep and lowering of body temperature. Further pharmacological actions include inhibition of platelet aggregation and relaxation of vascular smooth muscle. tetranor-<wbr></wbr>PGDM is a major metabolite of PGD<sub>2</sub> that is detectable in human and mouse urine. The levels of tetranor-<wbr></wbr>PGDM and 2,3-<wbr></wbr>dinor-<wbr></wbr>11β-<wbr></wbr>PGF<sub>2α</sub> (Item No. <span class=/itemid/>16530</span>), a related PGD<sub>2</sub> metabolite, in human urine were found to be 1.5 ± 0.3 and 0.6 ± ng/mg creatinine, respectively. tetranor-<wbr></wbr>PGDM was detected in murine urine at a level of 8.1 ± 1.3 ng/mg creatinine.
| Catalog Number | R015926 |
| CAS Number | 70803-91-7 |
| Synonyms | (1R,2R,3S)-2-(2-Carboxyethyl)-3-hydroxy-ε,5-dioxocyclopentaneoctanoic Acid; 11,15-Dioxo-9α-hydroxy-2,3,4,5-tetranorprostane-1,20-dioic Acid; [1R-(1α,2β,3β)]-2-(2-Carboxyethyl)-3-hydroxy-ε,5-dioxocyclopentaneoctanoic Acid |
| Molecular Formula | C16H24O7 |
| Purity | ≥95% |
| Target | Prostaglandin Receptor |
| Storage | -80°C |
| InChIKey | VNJBSPJILLFAIC-BZPMIXESSA-N |
